Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.
Browning S, Li F, Parker T, Bar N, Anderson T, Stevens E, VanOudenhove J, Matthews M, Gorshein E, Talsania A, Sabbath K, Seropian S, Halene S, Neparidze N. Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma. Journal Of Clinical Oncology 2024, 42: 7559-7559. DOI: 10.1200/jco.2024.42.16_suppl.7559.
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.
Browning S, Li F, Parker T, Bar N, Anderson T, Stevens E, VanOudenhove J, Matthews M, Gorshein E, Talsania A, Sabbath K, Seropian S, Halene S, Neparidze N. Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma. Journal Of Clinical Oncology 2024, 42: 7559-7559. DOI: 10.1200/jco.2024.42.16_suppl.7559.